Test Matrix Sample Clauses

Test Matrix. Table 3-1 presents the sampling and analytical matrix to be used at the MHF Test. Emissions/Offgas sampling shall be at the * sampling location. Offgas grab samples will be taken and analyzed by an Independent Lab. Sampling/testing will not be initiated until the start-up procedures have been completed and MHFs have stabilized at the desired production rate for the test. Exhibit 10.50(b) to Form 10-Q for the Quarter Ended September 30, 2008 filed by ADA-ES, Inc. (File No. 000-50216) on November 7, 2008 * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * Exhibit 10.50(b) to Form 10-Q for the Quarter Ended September 30, 2008 filed by ADA-ES, Inc. (File No. 000-50216) on November 7, 2008
AutoNDA by SimpleDocs
Test Matrix. Table 3-1 presents the sampling and analytical matrix to be used at the MHF Test. Emissions/Offgas sampling shall be at the * sampling location. Offgas grab samples will be taken and analyzed by an Xxxxxxxxxxx Lab. Sampling/testing will not be initiated until the start-up procedures have been completed and MHFs have stabilized at the desired production rate for the test. * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
Test Matrix. A sample of forty-two Ro-Ro vessels is utilised to form a suitable matrix that allows for meaningful comparisons between the various methods of assessing damage survivability as well as between the routes to ensuring compliance with current survivability standards. The main aim of this study is to present a critical evaluation of the emerging trends concerning the level of safety provided by the current damaged survivability standards for Ro-Ro vessels with the focus on the Stockholm Agreement requirements. More specifically, the study addresses the following methods and associated parameters: • SOLAS ’90 [GZmax, Positive GZ Range, Area under GZ Curve] • Stockholm Agreement Calculations [Limiting Hs] • Numerical Simulations [Limiting Hs] • Model Experiments [Limiting Hs] In addition to the above, the residual freeboard and damaged GMT are also considered. The sample of ships considered includes ships ranging in length from 85m to 205m and in damage stability standards from SOLAS ’74 to SOLAS ’90. The relevant details concerning the vessels in question together with the results pertaining to the damage survivability assessment according to the aforementioned methods are presented in Appendix A (available in “More MT Online” on the Web) with the operational sea states given in Table 2. Analysis of these results allowed for illustration of trends, consistency and relative significance between the methods used. A typical sample is shown in Figures 7 to 10.
Test Matrix. Tab. 1 gives an overview of the cyclic tests. The cyclic tests may contain a single load block or multiple load blocks. The cyclic tests can be divided into three main types: Constant amplitude tests (denoted by CA in the test ID), two-level block loading tests similar to Fig. 2-1 (denoted by BL in the test ID), and multi-level block loading demonstrator tests (denoted by DEM in the test ID). All cyclic tests are performed in -)control. The applied bending moment will be expressed as a fraction of the Ö fracture toughness of the material system ) =æ
Test Matrix. Table 3-1 presents the sampling and analytical matrix to be used at the MHF Test. Emissions/Offgas sampling shall be at the * sampling location. Offgas grab samples will be taken and analyzed by an Independent Lab. Sampling/testing will not be initiated until the start-up procedures have been completed and MHFs have stabilized at the desired production rate for the test.

Related to Test Matrix

  • Project Specific Milestones In addition to the milestones stated in Section 212.5 of the Tariff, as applicable, during the term of this ISA, Interconnection Customer shall ensure that it meets each of the following development milestones: 6.1 Substantial Site work completed. On or before December 31, 2020 Interconnection Customer must demonstrate completion of at least 20% of project site construction. At this time, Interconnection Customer must submit to Interconnected Transmission Owner and Transmission Provider initial drawings, certified by a professional engineer, of the Customer Interconnection Facilities. 6.2 Delivery of major electrical equipment. On or before December 31, 2021, Interconnection Customer must demonstrate that all generating units have been delivered to Interconnection Customer’s project site.

  • Targets and Milestones You may choose to develop specific additional targets and milestones which assess your performance in ITT over time – particularly if ITT trainees make up a significant proportion of your overall student body. Alternatively, you may have targets and milestones in your existing 2012-13 access agreement which you now also wish to apply to undergraduate and/or postgraduate ITT trainees. These targets may be statistical – based on how representative your entrants are and/or your retention performance – and might include annual or interim milestones to help you monitor whether you are making progress. You may wish to include criteria around the numbers of trainees in receipt of a full or partial maintenance grant, as financial data will need to be collected to determine bursary support and the data will also be accessible through the Student Loans Company for HEBSS subscribers. You may also wish to consider the TDA guidance at Annex C which gives information on specific groups that are underrepresented in the teaching profession.

  • Sales Milestones (a) As to each Therapeutic Product, SANOFI-AVENTIS shall pay MERRIMACK up to a total of Sixty Million Dollars (US$60,000,000) upon the first achievement of the following Net Sales milestones, on a Therapeutic Product-by-Therapeutic Product basis: (i) Total Worldwide Net Sales for such Therapeutic Product exceed $[**] in any four (4) consecutive calendar quarters $ [**] (ii) Total Worldwide Net Sales for such Therapeutic Product exceed $[**] in any four (4) consecutive calendar quarters $ [**] (iii) Total Worldwide Net Sales for Therapeutic Product exceed $[**] in any four (4) consecutive calendar quarters $ [**] (b) Each milestone payment set forth in Section 8.4(a) shall be payable by SANOFI-AVENTIS upon the achievement of the related milestone event by SANOFI-AVENTIS and its Affiliates or sublicensees, and SANOFI-AVENTIS shall provide notice to MERRIMACK promptly upon achievement of such milestone event. SANOFI-AVENTIS shall pay MERRIMACK each such milestone payment within [**] days of such achievement of the related milestone event. (c) For purposes of clarity, more than one of the Net Sales milestones set forth above may be earned in the same four (4) consecutive calendar quarter period with respect to a Therapeutic Product. For example, if total worldwide Net Sales with respect to a given Therapeutic Product have not achieved any of the lower sales milestone thresholds set forth in clause (i) or (ii) of Section 8.3(a) above in any previous four (4) consecutive calendar quarter period, but total worldwide Net Sales with respect to such Therapeutic Product exceed $[**] in a subsequent four (4) consecutive calendar quarter period, then all three milestone payments, totaling $60 Million, payable upon achievement of the sales milestone thresholds set forth in clause (i), (ii) and (iii) of Section 8.3(a) above shall become payable to MERRIMACK hereunder.

  • Milestone Schedule Please state the status and progress of each Milestone and identify any completed Milestone(s) for the previous calendar quarter.

  • ATTACHMENT C STANDARD STATE PROVISIONS FOR CONTRACTS AND GRANTS

  • Project/Milestones Taxpayer provides refrigerated warehousing and logistic distribution services to clients throughout the United States. In consideration for the Credit, Taxpayer agrees to invest in a new refrigeration and distribution facility in the XxXxxxxxx Park area of Sacramento, California, and hire full-time employees (collectively, the “Project”). Further, Taxpayer agrees to satisfy the milestones as described in Exhibit A (“Milestones”) and must maintain Milestones for a minimum of three (3) taxable years thereafter. In the event Taxpayer employs more than the number of full-time employees, determined on an annual full-time equivalent basis, than required in Exhibit A, for purposes of satisfying the “Minimum Annual Salary of California Full-time Employees Hired” and the “Cumulative Average Annual Salary of California Full-time Employees Hired,” Taxpayer may use the salaries of any of the full-time employees hired within the required time period. For purposes of calculating the “Minimum Annual Salary of California Full-time Employees Hired” and the “Cumulative Average Annual Salary of California Full-time Employees Hired,” the salary of any full-time employee that is not employed by Taxpayer for the entire taxable year shall be annualized. In addition, the salary of any full-time employee hired to fill a vacated position in which a full-time employee was employed during Taxpayer’s Base Year shall be disregarded.

  • Target Population TREATMENT FOR ADULT (TRA) Target Population

  • SCHEDULE AND MILESTONES The Parties shall execute one (1) Annex concurrently with this Umbrella Agreement. The initial Annex and any subsequent Annexes will be performed on the schedule and in accordance with the milestones set forth in each respective Annex.

  • Development Milestones In addition to its obligations under Paragraph 7.1, LICENSEE specifically commits to achieving (either itself or through the acts of a SUBLICENSEE) the following development milestones in its diligence activities under this AGREEMENT: (a) (b).

  • Milestones Subject to the provisions of the SGIP, the Parties shall agree on milestones for which each Party is responsible and list them in Attachment 4 of this Agreement. A Party’s obligations under this provision may be extended by agreement. If a Party anticipates that it will be unable to meet a milestone for any reason other than a Force Majeure event, it shall immediately notify the other Parties of the reason(s) for not meeting the milestone and (1) propose the earliest reasonable alternate date by which it can attain this and future milestones, and (2) requesting appropriate amendments to Attachment 4. The Party affected by the failure to meet a milestone shall not unreasonably withhold agreement to such an amendment unless it will suffer significant uncompensated economic or operational harm from the delay, (1) attainment of the same milestone has previously been delayed, or (2) it has reason to believe that the delay in meeting the milestone is intentional or unwarranted notwithstanding the circumstances explained by the Party proposing the amendment.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!